Anatomy & Physiology Study Guide
22

Blood

Chapter 22Fluids and Transport7.5 h5 sections, outcomes 1-31Week 17

Slide deck, 35 slidesFlashcards, 102Practice questions, 60 in the bank

22.1

Composition of Blood, Plasma, and Hematopoiesis

1.5 hMonday, Mar 8, Week 17

Outcomes

  1. 1Describe the components of whole blood, plasma and formed elements and calculate hematocrit and plasma fraction from a centrifuged tube.
  2. 2Classify plasma proteins by origin and function, including albumin, globulins, fibrinogen and their contribution to oncotic pressure.
  3. 3Give the reference values for blood volume, pH, viscosity and osmolality and explain what changes each spot-check.
  4. 4Trace hematopoiesis from the hematopoietic stem cell through myeloid and lymphoid progenitors to each mature cell line.
  5. 5Name the sites of blood cell formation across fetal life, childhood and adulthood and the cytokines that drive each lineage.
  6. 6Recognize bone marrow cell lineages and red versus yellow marrow on marrow smears and sections.

Outline

  1. A

    Composition and physical properties

    1. Whole blood is about 55 percent plasma, 45 percent cells (mostly RBCs), a buffy coat of WBCs and platelets under 1 percent spot-check.
    2. Hematocrit about 41-50 percent in men and 36-44 percent in women spot-check; low in anemia, high in polycythemia and dehydration.
    3. Total blood volume roughly 5 L (about 7-8 percent of body mass, 70-80 mL/kg) spot-check; pH 7.35-7.45; viscosity about 3-4 times water, mostly from RBCs; mildly warmer than core temperature.
    4. Serum is plasma without clotting factors, i.e. what remains after clot formation.
    5. Whole blood is a non-Newtonian fluid; higher hematocrit raises viscosity and resistance to flow.
  2. B

    Plasma

    1. Plasma is about 92 percent water with proteins (6-8 g/dL total) spot-check, electrolytes (Na+ the dominant cation), nutrients, wastes, gases and hormones.
    2. Albumin (about 60 percent of protein; made by the liver) supplies most oncotic pressure and carries fatty acids, bilirubin, drugs and hormones spot-check.
    3. Globulins: alpha and beta (transport, e.g. transferrin, ceruloplasmin, lipoproteins, complement) and gamma (immunoglobulins made by plasma cells).
    4. Fibrinogen (factor I, about 4 percent) converts to fibrin; its loss defines serum.
    5. Hypoalbuminemia (liver disease, nephrotic syndrome, malnutrition) lowers oncotic pressure and causes edema.
    6. Plasma oncotic pressure about 25 mm Hg opposes capillary filtration spot-check.
  3. C

    Hematopoietic hierarchy and growth factors

    1. Pluripotent hematopoietic stem cells (CD34+) self-renew and differentiate into common myeloid progenitors (CMP) and common lymphoid progenitors (CLP).
    2. CMP gives megakaryocyte-erythroid progenitors (to RBCs and platelets) and granulocyte-monocyte progenitors (neutrophils, eosinophils, basophils, monocytes); CLP gives T, B and NK cells.
    3. Key cytokines: stem cell factor and IL-3 (multilineage), erythropoietin (RBC), thrombopoietin (platelets), G-CSF (neutrophils), GM-CSF, M-CSF (monocytes), IL-5 (eosinophils), IL-7 (lymphoid).
    4. Bone marrow stromal niche (fibroblasts, endothelium, osteoblasts, macrophages) supplies SCF, CXCL12 and adhesion.
    5. Clinical use: G-CSF mobilizes stem cells for bone marrow or cord-blood transplantation; CD34 counts guide collection.
  4. D

    Sites and structure of marrow

    1. Yolk sac (weeks 3-8), then liver and spleen (months 2-7), then marrow takes over from the fifth month onward.
    2. Newborn marrow is red throughout; in adults hematopoiesis is limited to the axial skeleton, proximal femur and humerus.
    3. Yellow (fatty) marrow occupies long bone shafts and can revert to red marrow in severe demand.
    4. Marrow sinusoids have fenestrated endothelium; megakaryocytes extend proplatelets into the lumen; mature cells cross by transmigration.
    5. Marrow trephine (iliac crest) and aspirate are the diagnostic samples.

Lab

  • Draw the hematopoietic tree with cytokines at each branch point and cover it to retest.
  • Histology Guide MH-034bhr: sequence erythroid (proerythroblast to orthochromatic normoblast) and granulocytic (myeloblast to band) maturation stages in the marrow smear.
  • Identify megakaryocytes, adipocytes and sinusoids on MH-034a and MHS-304.
  • Work three hematocrit problems from centrifuged tube heights, and compute plasma volume from hematocrit and total blood volume.
22.2

Erythrocytes, Hemoglobin, Iron, and Erythropoiesis

1.5 hTuesday, Mar 9, Week 17

Outcomes

  1. 7Describe the biconcave RBC shape, membrane cytoskeleton and anucleate metabolism and explain how they support gas transport and deformability.
  2. 8Explain the structure of adult, fetal and variant hemoglobin, including heme, globin chains and the cooperative binding that shapes the oxyhemoglobin dissociation curve.
  3. 9Describe regulation of erythropoietin by renal hypoxia through HIF and predict its response to altitude, anemia and renal failure.
  4. 10Trace dietary iron absorption, transport, storage and recycling, including hepcidin.
  5. 11Explain the roles of vitamin B12 and folate in DNA synthesis and the absorption of B12 requiring intrinsic factor.
  6. 12Classify anemias by MCV and mechanism and interpret hemoglobin, MCV, reticulocyte count and iron studies.
  7. 13Trace RBC senescence and heme catabolism to unconjugated bilirubin and describe jaundice types.

Outline

  1. A

    RBC structure and metabolism

    1. 7-8 micrometre biconcave anucleate discs with surface-to-volume ratio supporting deformation through 3-micrometre capillaries and splenic cords.
    2. Cytoskeleton of spectrin, ankyrin, band 3 and protein 4.1 anchors the membrane; defects give hereditary spherocytosis (ankyrin/spectrin) and elliptocytosis.
    3. No mitochondria: glycolysis supplies ATP; the pentose phosphate pathway makes NADPH for glutathione, so G6PD deficiency gives oxidant hemolysis with Heinz bodies.
    4. Carbonic anhydrase and band 3 chloride-bicarbonate exchange carry most CO2 as HCO3-.
    5. Lifespan about 120 days spot-check; counts about 4.5-5.9 x10^12/L men and 4.0-5.2 x10^12/L women spot-check.
  2. B

    Hemoglobin structure and variants

    1. HbA is a tetramer (alpha2 beta2) with four heme groups, each with Fe2+ binding one O2; T (tense) to R (relaxed) transition produces the sigmoid curve.
    2. HbA2 (alpha2 delta2) under 3.5 percent and HbF (alpha2 gamma2) about 1 percent in adults; HbF binds 2,3-BPG poorly and has higher O2 affinity, supporting placental transfer spot-check.
    3. Right shift (lower affinity) with high CO2, H+ (Bohr effect), temperature and 2,3-BPG; left shift with the opposite, and with CO and HbF.
    4. Sickle cell disease: Glu6Val in beta globin, HbS polymerizes when deoxygenated, causing sickling, vaso-occlusion and hemolysis; heterozygotes (trait) have malaria resistance.
    5. Thalassemias: reduced alpha or beta chain synthesis gives microcytic anemia with unbalanced chains; methemoglobin has Fe3+ and cannot carry O2.
    6. Heme synthesis (ALA synthase, vitamin B6, lead inhibits ALA dehydratase and ferrochelatase) in mitochondria and cytoplasm.
  3. C

    Erythropoiesis and erythropoietin

    1. Sequence: proerythroblast, basophilic, polychromatic and orthochromatic erythroblast, enucleation, reticulocyte (1-2 percent of RBCs in blood, polychromatic with residual RNA), mature RBC spot-check.
    2. EPO is made by peritubular interstitial fibroblast-like cells in the renal cortex (liver in fetus) in response to low tissue O2.
    3. Under normoxia prolyl hydroxylase tags HIF-alpha for VHL-mediated degradation; hypoxia stabilizes HIF, which raises EPO transcription.
    4. EPO acts on CFU-E and proerythroblasts through the EPO receptor-JAK2-STAT5 pathway to prevent apoptosis.
    5. Anemia of chronic kidney disease responds to recombinant EPO; polycythemia vera has JAK2 V617F with low EPO; EPO abuse is a doping concern.
  4. D

    Iron, B12 and folate

    1. Body iron about 3-4 g, mostly in hemoglobin; heme iron is absorbed better than non-heme iron; duodenal DMT1 takes up Fe2+ (after DcytB reduction), ferroportin exports it.
    2. Transport on transferrin; storage as ferritin (and hemosiderin); transferrin receptor 1 delivers iron to erythroblasts.
    3. Hepcidin from the liver blocks ferroportin; rises with inflammation (anemia of chronic disease) and falls in iron deficiency.
    4. Iron deficiency: low ferritin, high TIBC, microcytic hypochromic cells; iron overload (hemochromatosis) shows high ferritin and transferrin saturation.
    5. B12 requires intrinsic factor from gastric parietal cells and is absorbed in the terminal ileum; stores last years; deficiency also causes subacute combined degeneration of the spinal cord.
    6. Folate absorption occurs in the jejunum; stores last months; both deficiencies impair thymidylate synthesis and give megaloblastic anemia with hypersegmented neutrophils.
    7. Elevated methylmalonic acid separates B12 from folate deficiency.
  5. E

    Anemia classification and RBC destruction

    1. Microcytic (MCV under 80 fL): iron deficiency, thalassemia, anemia of chronic disease, sideroblastic; normocytic: acute blood loss, hemolysis, renal disease; macrocytic (over 100 fL): B12/folate deficiency, liver disease, alcohol spot-check.
    2. Aplastic anemia is pancytopenia with hypocellular marrow.
    3. Macrophages in spleen and liver phagocytose aged RBCs; heme to biliverdin to unconjugated bilirubin (albumin-bound) to liver conjugation to bile and urobilinogen.
    4. Hemolysis raises indirect bilirubin, LDH and reticulocytes and lowers haptoglobin; neonatal jaundice follows from immature conjugation.

Lab

  • Histology Guide MH-033: find erythrocytes, estimate the central pallor ratio and compare size with a small lymphocyte nucleus.
  • Histology Guide MH-033hr: identify a reticulocyte or polychromatic RBC if present and note anisocytosis.
  • Sketch an oxyhemoglobin dissociation curve showing right and left shifts and HbF, annotating P50.
  • Interpret four case panels (Hb, MCV, reticulocytes, ferritin, TIBC, B12) and name the anemia.
  • Make a flow diagram of iron from gut to marrow to macrophage and back, marking hepcidin.
22.3

Leukocytes and Platelets

1.5 hWednesday, Mar 10, Week 17

Outcomes

  1. 14Identify the five leukocyte types on a Wright-stained smear using size, nuclear shape, chromatin and granule color.
  2. 15Give the reference differential and absolute counts for each leukocyte type and state the causes of common shifts spot-check.
  3. 16Describe the neutrophil, monocyte, eosinophil and basophil responses to infection and allergic disease at overview level.
  4. 17Trace platelet formation from megakaryocyte under thrombopoietin and describe the platelet granules and membrane features.
  5. 18Interpret leukocytosis, leukopenia, thrombocytopenia and thrombocytosis and the left shift.

Outline

  1. A

    Granulocytes on smear

    1. Neutrophil (50-70 percent; 12-15 micrometres): 3-5 lobed nucleus, pale pink fine granules; bands have a U-shaped nucleus; females may show a drumstick (Barr body).
    2. Eosinophil (1-4 percent): bilobed nucleus with large bright red-orange granules; rise in parasites, allergy, drug reaction.
    3. Basophil (under 1 percent): lobed nucleus obscured by large dark purple granules containing histamine and heparin; rise in myeloproliferative disease.
    4. Left shift is increased bands and immature forms in infection; hypersegmentation (over 5 lobes) suggests megaloblastic anemia.
    5. Neutrophil lifespan hours in blood, days in tissue; marginating pool equals circulating pool; stress, steroids and epinephrine demarginate cells.
  2. B

    Agranulocytes on smear

    1. Lymphocyte (20-40 percent): round dark nucleus occupying most of a small cell with thin blue cytoplasm; large granular lymphocytes are NK cells.
    2. Monocyte (2-8 percent; largest, 15-20 micrometres): indented kidney or horseshoe nucleus, gray-blue cytoplasm with fine vacuoles; becomes tissue macrophage.
    3. Reactive (atypical) lymphocytes in infectious mononucleosis are large with abundant cytoplasm.
    4. Normal total WBC 4-11 x10^9/L spot-check; identify by counting 100 cells in a differential and multiplying by total count for absolute values.
    5. Mnemonic order by abundance: neutrophils, lymphocytes, monocytes, eosinophils, basophils.
  3. C

    Leukocyte functions (overview)

    1. Neutrophils: diapedesis, chemotaxis, phagocytosis and respiratory burst (NADPH oxidase; deficient in chronic granulomatous disease).
    2. Eosinophils: anti-parasitic and modulate allergy; basophils and mast cells: IgE-triggered histamine release.
    3. Monocytes and macrophages: phagocytosis and antigen presentation; lymphocyte function is covered in chapter 26.
    4. Leukopenia and neutropenia (under 1.5 x10^9/L) increase infection risk; leukemias show uncontrolled proliferation of a lineage.
  4. D

    Platelets

    1. Fragments of megakaryocyte cytoplasm, 2-3 micrometres, anucleate, lifespan 7-10 days, count 150-400 x10^9/L spot-check.
    2. Thrombopoietin (liver) binds platelet and megakaryocyte c-Mpl receptors and is cleared by them; megakaryocytes are polyploid and shed proplatelets in marrow sinusoids; about one-third of platelets are splenic.
    3. Structure: glycocalyx with GPIb and GPIIb/IIIa, open canalicular system, dense tubular system, alpha granules (vWF, fibrinogen, PDGF) and dense granules (ADP, ATP, serotonin, Ca2+).
    4. Smear appearance: small purple granular clusters; use them to estimate count.
    5. Thrombocytopenia (under 150 x10^9/L; bleeding often when under 50, spontaneous under 10-20) from ITP, TTP, DIC, heparin-induced thrombocytopenia or marrow failure.

Lab

  • Histology Guide MH-033hr: identify each leukocyte type on the blood smear and name the single feature that separates it from its look-alike.
  • R&P plates 16 and 17: label neutrophil, eosinophil, basophil, lymphocyte, monocyte and platelet.
  • Perform a 100-cell differential on a smear image set, convert to absolute counts for a given WBC, and decide which values are abnormal.
  • Compare a neutrophil band and a monocyte side by side and write the three distinguishing criteria.
22.4

Hemostasis and Coagulation

2 hThursday, Mar 11, Week 17

Outcomes

  1. 19Sequence vascular spasm, platelet plug formation (adhesion, activation, aggregation) and coagulation in a bleeding injury.
  2. 20Diagram the intrinsic, extrinsic and common coagulation pathways with factors, cofactors, calcium and phospholipid surface.
  3. 21Explain the cell-based model of coagulation as initiation, amplification and propagation on cell surfaces.
  4. 22Interpret PT/INR, aPTT, thrombin time, platelet count and fibrinogen results and predict which factors or drugs they reflect.
  5. 23Describe the roles of vitamin K, thrombin, factor XIII and fibrin in clot formation and the vitamin K dependent factors.
  6. 24Explain the anticoagulant and fibrinolytic systems: antithrombin, protein C/S, TFPI, plasmin, tPA and PAI-1.
  7. 25Relate hemophilia A and B, von Willebrand disease, DIC, thrombosis and anticoagulant drugs to specific steps of hemostasis.

Outline

  1. A

    Primary hemostasis

    1. Vascular spasm: smooth muscle contraction from local myogenic response, endothelin and thromboxane A2, lasting minutes.
    2. Adhesion: exposed collagen binds von Willebrand factor, which captures platelets via GPIb.
    3. Activation: platelets change shape, release ADP and serotonin (dense granules) and make thromboxane A2 (COX-1; blocked by aspirin).
    4. Aggregation: GPIIb/IIIa binds fibrinogen bridges; clopidogrel blocks the P2Y12 ADP receptor, abciximab blocks IIb/IIIa.
    5. Intact endothelium resists clotting with NO, prostacyclin and thrombomodulin; defects in primary hemostasis give mucocutaneous bleeding and petechiae.
    6. Bernard-Soulier is GPIb deficiency; Glanzmann is IIb/IIIa deficiency; von Willebrand disease is the commonest inherited bleeding disorder.
  2. B

    Coagulation cascade

    1. Extrinsic pathway: tissue factor (III) plus VIIa, Ca2+ (IV), activates X; measured by PT.
    2. Intrinsic pathway: contact activation by XII, then XI, IX (with VIIIa), activates X on phospholipid; measured by aPTT.
    3. Common pathway: Xa with Va, Ca2+ and phospholipid (prothrombinase) converts prothrombin (II) to thrombin (IIa); thrombin converts fibrinogen (I) to fibrin and activates V, VIII, XI and XIII.
    4. Factor XIIIa cross-links fibrin to stabilize the clot; platelets retract the clot via actin/myosin.
    5. Cell-based model: tissue factor on fibroblasts initiates a small thrombin burst, which activates platelets and cofactors (amplification), then tenase and prothrombinase on platelets drive a large thrombin burst (propagation).
    6. In vivo, the extrinsic path is the physiologic trigger; the intrinsic path amplifies, which explains why XII deficiency does not cause bleeding.
  3. C

    Vitamin K and coagulation tests

    1. Vitamin K allows gamma-carboxylation of glutamate in factors II, VII, IX, X and proteins C and S, which is needed for Ca2+ and phospholipid binding.
    2. Warfarin blocks vitamin K epoxide reductase (VKORC1); factor VII has the shortest half-life, so PT prolongs first and early warfarin causes transient protein C deficiency (skin necrosis).
    3. PT (extrinsic and common: VII, X, V, II, I) reported as INR; aPTT (intrinsic and common: XII, XI, IX, VIII, X, V, II, I), monitors unfractionated heparin.
    4. Prolonged aPTT with normal PT: hemophilia A (VIII), hemophilia B (IX), XI, heparin; prolonged PT with normal aPTT: factor VII deficiency, early warfarin.
    5. A mixing study corrects a factor deficiency but not an inhibitor (lupus anticoagulant, factor antibody).
    6. Hemophilia A and B are X-linked recessive; hemarthrosis is typical; normal bleeding time and PT.
    7. Reference PT about 11-13.5 s, aPTT about 25-35 s spot-check; therapeutic INR commonly 2-3.
  4. D

    Natural anticoagulants

    1. Antithrombin neutralizes thrombin and Xa, accelerated about 1000-fold by heparin; low-molecular-weight heparin mainly acts on Xa.
    2. Protein C (activated by thrombin-thrombomodulin) with protein S inactivates Va and VIIIa; factor V Leiden resists this and is the commonest inherited thrombophilia.
    3. Tissue factor pathway inhibitor (TFPI) blocks VIIa-TF-Xa; endothelium also makes NO, prostacyclin and heparan sulfate.
    4. Direct oral anticoagulants inhibit Xa (rivaroxaban, apixaban) or thrombin (dabigatran).
  5. E

    Fibrinolysis

    1. tPA and urokinase convert plasminogen bound to fibrin into plasmin, which digests fibrin into fragments including D-dimer.
    2. Inhibitors: PAI-1 against tPA and alpha-2 antiplasmin against plasmin.
    3. Therapeutic tPA (alteplase) or streptokinase is used in stroke, MI and pulmonary embolism; tranexamic acid inhibits fibrinolysis.
    4. Elevated D-dimer indicates fibrin turnover and is a screening test (high negative predictive value) for venous thromboembolism.
  6. F

    Pathology of hemostasis

    1. Virchow triad: stasis, endothelial injury and hypercoagulability drive thrombosis; deep vein thrombosis can embolize to the lung.
    2. DIC: widespread activation consumes platelets and fibrinogen, giving prolonged PT/aPTT, low platelets and high D-dimer.
    3. Liver disease impairs synthesis of most factors (except VIII), prolonging PT; vitamin K deficiency occurs in malabsorption and newborns.
    4. Heparin-induced thrombocytopenia is paradoxically prothrombotic due to anti-PF4/heparin antibodies.

Lab

  • Draw the cascade with Roman-numeral factors, label which arm PT and aPTT measure, and mark where warfarin, heparin and DOACs act.
  • Interpret a set of six coagulation panels (PT, aPTT, platelets, fibrinogen, D-dimer) for diagnoses such as hemophilia A, early warfarin, DIC, ITP and von Willebrand disease.
  • Sequence the platelet plug steps from injury to stable clot as a labelled storyboard.
  • Histology Guide MH-033hr: locate platelets on the smear and describe the clumping pattern.
22.5

Blood Groups and Transfusion

1 hFriday, Mar 12, Week 17

Outcomes

  1. 26Explain the ABO antigens, their biochemical basis in the H antigen and the naturally occurring antibodies.
  2. 27Predict the possible offspring phenotypes of an ABO and Rh cross using the genotypes.
  3. 28Compare the Rh system antigens with ABO antibodies by immunoglobulin class and clinical significance.
  4. 29Determine donor-recipient compatibility for red cells and plasma and describe the steps of the crossmatch.
  5. 30Explain hemolytic disease of the fetus and newborn and the role of anti-D prophylaxis.
  6. 31Describe the acute and delayed hemolytic and non-hemolytic transfusion reactions and the initial management.

Outline

  1. A

    ABO system

    1. Antigens are carbohydrates on the RBC membrane built on the H antigen by glycosyltransferases from the ABO gene (chromosome 9): A adds N-acetylgalactosamine, B adds galactose, O is an inactive enzyme.
    2. A and B alleles are codominant; O is recessive; genotypes AA/AO give group A, BB/BO group B, AB group AB, OO group O.
    3. Naturally occurring IgM antibodies against the missing antigens develop in infancy through exposure to gut bacteria.
    4. Group O has anti-A and anti-B (universal red cell donor) and AB has neither (universal red cell recipient, universal plasma donor); O blood has H antigen only.
    5. Bombay phenotype lacks H antigen and so types as O but cannot receive O blood spot-check.
    6. Frequencies in the US: O about 45 percent, A about 40 percent, B about 11 percent, AB about 4 percent spot-check.
  2. B

    Rh system

    1. Rh is multi-antigen; D antigen is the clinically dominant protein (RHD gene); D-positive about 85 percent of white populations spot-check.
    2. Anti-D forms only after exposure (transfusion, pregnancy); it is IgG and crosses the placenta, unlike ABO IgM.
    3. Genetics: D is dominant; Rh-negative is homozygous recessive (dd).
    4. A first sensitizing pregnancy is generally unaffected; later Rh-positive fetuses are at risk.
  3. C

    Transfusion practice

    1. Type and screen: ABO/Rh typing by forward (cells) and reverse (serum) agglutination and antibody screen by indirect Coombs test.
    2. Crossmatch: mixing donor red cells with recipient serum to detect incompatibility; immediate-spin for ABO, antiglobulin phase for IgG antibodies.
    3. Choose red cells compatible with recipient plasma antibodies (O cells to anyone) and plasma compatible with recipient cells (AB plasma to anyone); Rh-negative females of child-bearing potential receive D-negative products.
    4. Acute hemolytic reaction (ABO mismatch): intravascular hemolysis with fever, hypotension, flank pain, hemoglobinuria, DIC; stop transfusion and check labeling.
    5. Febrile non-hemolytic (leukocyte cytokines), allergic/anaphylactic (IgA deficiency), TRALI (donor anti-HLA antibodies) and TACO (volume overload) are other reactions.
    6. Direct Coombs test detects antibody on patient RBCs (HDFN, autoimmune hemolysis).
  4. D

    Hemolytic disease of the fetus and newborn

    1. Mechanism: Rh-negative mother sensitized by fetomaternal hemorrhage (at delivery, miscarriage or amniocentesis) makes IgG anti-D that crosses the placenta in later D-positive pregnancies.
    2. Fetal findings: hemolytic anemia, hydrops fetalis, extramedullary hematopoiesis (hepatosplenomegaly), neonatal hyperbilirubinemia and kernicterus.
    3. Prevention: anti-D immune globulin (RhoGAM) at 28 weeks and within 72 h after delivery of a D-positive baby, with extra dose guided by Kleihauer-Betke test or flow cytometry spot-check.
    4. ABO incompatibility (mother O, baby A or B) is more common but usually milder, and can affect a first pregnancy.
    5. Monitoring uses maternal antibody titers and middle cerebral artery Doppler; treatment includes intrauterine transfusion.

Lab

  • Draw an agglutination grid for forward and reverse typing of the four ABO groups with Rh positive and negative.
  • Work four Punnett squares for ABO and Rh parent crosses and list possible offspring phenotypes.
  • Complete a crossmatch decision table for eight donor-recipient pairs, marking red-cell and plasma compatibility.
  • Walk through a case of an Rh-negative mother with a second Rh-positive pregnancy and map prophylaxis timing.

Teach-back prompts

  1. Follow one hematopoietic stem cell to a mature RBC, naming the cytokine, the oxygen-sensing mechanism that controls it and the nutrients that cell line needs.
  2. Identify the five leukocytes and the platelet on a smear by describing, aloud, the distinguishing features of each.
  3. Walk through hemostasis from endothelial injury to a stabilized clot, and explain what PT and aPTT each measure and which drug or disease changes them.
  4. Explain ABO and Rh genetics and how a second pregnancy with an Rh-positive fetus can produce hemolytic disease, and how it is prevented.

Practical targets

  • Erythrocyte on peripheral smear (Histology Guide MH-033)
  • Neutrophil (R&P plate 17)
  • Eosinophil (R&P plate 17)
  • Basophil (R&P plate 17)
  • Lymphocyte (R&P plate 16)
  • Monocyte (R&P plate 16)
  • Platelets on smear (Histology Guide MH-033hr)
  • Megakaryocyte in bone marrow (Histology Guide MH-034bhr)
  • Erythroblast stages in marrow smear (Histology Guide MH-034a)
  • Granulocyte precursors (myelocyte, metamyelocyte, band) in marrow (Histology Guide MH-034bhr)
  • Adipocytes and sinusoids in marrow section (Histology Guide MHS-304)
  • Composition of blood diagram (NET plate BP15)

Also see